Literature DB >> 2566380

Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver.

R C Cattley1, J A Popp.   

Abstract

In order to characterize the promoting activity of the peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (WY-14,463), male F344 rats which received a single 150-mg/kg dose of diethylnitrosamine (DEN) were fed 0.1% WY-14,643 or 0.05% phenobarbital in the diet for 11, 22, or 54 wk. WY-14,643 promoted the development of ATPase-deficient foci but not GGTase-positive or G6Pase-deficient foci, in contrast to phenobarbital which promoted development of foci detected by all three markers. The mode of promotion of ATPase-deficient foci by WY-14,643 was distinctly different from that of phenobarbital. WY-14,643 primarily increased mean volume of foci at 11 and 22 wk, while phenobarbital primarily increased the numerical density of foci at these time points. At 54 wk, the yield of hepatic neoplasms per liver was higher in rats fed WY-14,643 than in rats fed phenobarbital. To evaluate the possibility that the promotional activity of WY-14,643 was more effective at a later stage in hepatocarcinogenesis, rats receiving a dose of DEN and then phenobarbital in the diet for 11 wk were changed to a diet containing WY-14,643 for an additional 11 or 43 wk. However, WY-14,643 feeding from wk 11 to 22 caused a reduction in volume density of ATPase-deficient foci relative to the volume density of foci at 11 wk. In addition, feeding WY-14,643 from wk 11 to 54 caused similar yields of hepatic neoplasms whether or not phenobarbital was fed for the initial 11 wk. WY-14,643 induced hepatic peroxisome proliferation as indicated by palmitoyl CoA oxidase activity regardless of prior treatment with DEN and/or phenobarbital. The yield of neoplasms in rats not receiving DEN was greater in rats fed WY-14,643 for wk 11 to 54 than in rats fed WY-14,643 for wk 1 to 54. In summary, the peroxisome proliferator WY-14,643 was a more efficient promoter of hepatocarcinogenesis in DEN-initiated rats than phenobarbital. The promotional activity of WY-14,643, when evaluated by stereological analysis and by changing promoters, is distinct from that of phenobarbital, perhaps suggesting different cellular and/or molecular mechanisms of promotion. Understanding the role of promotion by WY-14,643 and other peroxisome proliferators may be important in understanding the mechanism of their hepatocarcinogenicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566380

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Phenobarbital does not reduce the concentration of thyroid hormone in CC57BR mice in which it does not promote liver tumor development.

Authors:  V I Kaledin; T A Obut
Journal:  Dokl Biol Sci       Date:  2003 Nov-Dec

2.  Suppression of agonist induced Ca2+ oscillations in cultured hepatocytes by nafenopin: possible involvement of protein kinase C.

Authors:  E Leibold; A Stampfl; L R Schwarz
Journal:  Arch Toxicol       Date:  1996       Impact factor: 5.153

Review 3.  Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver.

Authors:  Ivan Rusyn; Jeffrey M Peters; Michael L Cunningham
Journal:  Crit Rev Toxicol       Date:  2006-05       Impact factor: 5.635

4.  Liver fatty acid-binding protein: specific mediator of the mitogenesis induced by two classes of carcinogenic peroxisome proliferators.

Authors:  S H Khan; S Sorof
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

5.  Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression.

Authors:  S L Marcus; K S Miyata; B Zhang; S Subramani; R A Rachubinski; J P Capone
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 6.  Modulation of mitogenesis by liver fatty acid binding protein.

Authors:  S Sorof
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 7.  The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.

Authors:  J Christopher Corton; Jeffrey M Peters; James E Klaunig
Journal:  Arch Toxicol       Date:  2017-12-02       Impact factor: 5.153

8.  From the Cover: Genomic Effects of Androstenedione and Sex-Specific Liver Cancer Susceptibility in Mice.

Authors:  John P Rooney; Natalia Ryan; Brian N Chorley; Susan D Hester; Elaina M Kenyon; Judith E Schmid; Barbara Jane George; Michael F Hughes; Yusupha M Sey; Alan Tennant; Denise K MacMillan; Jane Ellen Simmons; Charlene A McQueen; Arun Pandiri; Charles E Wood; J Christopher Corton
Journal:  Toxicol Sci       Date:  2017-11-01       Impact factor: 4.849

9.  Effect of dietary vitamin E on the development of altered hepatic foci and hepatic tumors induced by the peroxisome proliferator ciprofibrate.

Authors:  H P Glauert; M M Beaty; T D Clark; W S Greenwell; V Tatum; L C Chen; T Borges; T L Clark; S R Srinivasan; C K Chow
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

10.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene.

Authors:  J D Tugwood; I Issemann; R G Anderson; K R Bundell; W L McPheat; S Green
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.